May 14, 2018 / 1:17 PM / 2 months ago

BRIEF-Galectin Therapeutics Proceeds To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis

May 14 (Reuters) - Galectin Therapeutics Inc:

* GALECTIN THERAPEUTICS PROCEEDS TO PHASE 3 DEVELOPMENT OF GR-MD-02 FOR NASH CIRRHOSIS FOLLOWING FDA MEETING

* GALECTIN THERAPEUTICS INC - TARGET POPULATION OF PHASE 3 CLINICAL TRIAL WILL BE PATIENTS WITH NASH CIRRHOSIS WITHOUT ESOPHAGEAL VARICES

* GALECTIN THERAPEUTICS INC - “DISAGREE WITH FDA’S DECISION NOT TO GRANT BREAKTHROUGH THERAPY DESIGNATION AT THIS TIME”

* GALECTIN THERAPEUTICS - FDA HAS NOT GRANTED BREAKTHROUGH DESIGNATION FOR PATIENTS WITH NASH CIRRHOSIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below